CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine.
The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization. These VLVs generate superior immune responses (high antibody levels and specific CD4+ and CD8+ T cells required for complete protective immunity) than other vaccine technologies.
The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.
Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
HAMDEN, CT, August 20, 2013 – A corporate research agreement involving CaroGen Corporation’s novel recombinant virus-like vesicle (VLV) platform technology was signed between the Company and Yale University. CaroGen is a biotechnology firm pioneering breakthrough technology for the development of novel vaccines.